The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma

Recent Results in Cancer Research

Volumn 182, Issue , 2010, Pages 39-63

  Grotenhuis, Brechtje A ^a   Van Lanschot, J Jan B ^a   Dinjens, Winand N M ^a   Wijnhoven, Bas P L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; CYCLOOXYGENASE 2; CYTOKERATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PEPSIN A; TRANSFORMING GROWTH FACTOR BETA; TRYPSIN; VASCULOTROPIN;

ACIDITY; ALKALINITY; APOPTOSIS; BARRETT ESOPHAGUS; BODY MASS; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC GASTRITIS; COLUMNAR EPITHELIUM; DISEASE COURSE; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GOBLET CELL; HELICOBACTER INFECTION; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; LOWER ESOPHAGUS SPHINCTER; METAPLASIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH FUNDUS; UPREGULATION; ADENOCARCINOMA; COMPLICATION; ESOPHAGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ADENOCARCINOMA; APOPTOSIS; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; METAPLASIA; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS;

EID: 77956052951     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-70579-6_4     Document Type: Review

References (200)

1. Abdel-Latif MM, O'Riordan JM, Ravi N, Kelleher D, Reynolds JV (2005) Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis Esophagus 18:246-252
2. al-Kasspooles M, Moore JH, Orringer MB, Beer DG (1993) Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54:213-219
3. Allison PR, Johnstone AS (1953) The oesophagus lined with gastric mucous membrane. Thorax 8:87-101
4. Arber N, Lightdale C, Rotterdam H, Han KH, Sgambato A, Yap E, Ahsan H, Finegold J, Stevens PD, Green PH, Hibshoosh H, Neugut AI, Holt PR, Weinstein IB (1996) Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 5:457-459
5. Aste H, Bonelli L, Ferraris R, Conio M, Lapertosa G (1999) Gastroesophageal reflux disease: relationship between clinical and histological features. GOSPE. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago. Dig Dis Sci 44:2412-2418
6. Atherfold PA, Jankowski JA (2006) Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol 20:813-827
7. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M, Salo JA (2002) Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 20:2971-2979
8. Bahmanyar S, Zendehdel K, Nyren O, Ye W (2007) Risk of oesophageal cancer by histology among patients hospitalised for gastroduodenal ulcers. Gut 56:464-468
9. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J (1998) Altered cadherin and catenin complexes in the Barrett's esophagus- dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 152:135-144
10. Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP (2000) Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92:1316-1321
11. Barnes PJ, Karin M (1997) Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071
12. Barrett NR (1950) Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 38:175-182
13. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ (2005) Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5:899-904
14. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289
15. Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS (1997) Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterology 112:760-765
16. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau JH, Raskind WHet al. (1992) Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 89:3385-3388
17. Bremner CG, Lynch VP, Ellis FH Jr (1970) Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 68:209-216
18. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122:1800-1807
19. Buskens CJ, Ristimaki A, Offerhaus GJ, Richel DJ, van Lanschot JJ (2003) Role of cyclooxygenase- 2 in the development and treatment of oesophageal adenocarcinoma. Scand J Gastroenterol Suppl: 87-93
20. Buttar NS, Falk GW (2001) Pathogenesis of gastroesophageal reflux and Barrett esophagus. Mayo Clin Proc 76:226-234
21. Buttar NS, Wang KK (2004) Mechanisms of disease: carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 1:106-112
22. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, Lutzke LS (2002) The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 94:422-429
23. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP (1995) Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg 82:657-660
24. Cameron AJ, Lomboy CT (1992) Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103:1241-1245
25. Cameron AJ, Ott BJ, Payne WS (1985) The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313:857-859
26. Carney CN, Orlando RC, Powell DW, Dotson MM (1981) Morphologic alterations in early acidinduced epithelial injury of the rabbit esophagus. Lab Invest 45:198-208
27. Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P (2003) Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a tenyear prospective study. J Thorac Cardiovasc Surg 125:1121-1131
28. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R (1994) Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 107:747-754
29. Chandrasoma PT, DeMeester TR (2006) Does columnar-lined esophagus increase in length? Does Barrett esophagus increase in length? In: GERD: Reflux to esophageal adenocarcinoma. Elsevier, Oxford, pp 190-192
30. Chandrasoma PT, Der R, Ma Y, Peters J, Demeester T (2003) Histologic classification of patients based on mapping biopsies of the gastroesophageal junction. Am J Surg Pathol 27:929-936
31. Chang CL, Lao-Sirieix P, Save V, De La Cueva MG, Laskey R, Fitzgerald RC (2007) Retinoic acidinduced glandular differentiation of the oesophagus. Gut 56:906-917
32. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF Jr (1998) An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58: 588-590
33. Christofori G, Semb H (1999) The role of the cell- adhesion molecule E-cadherin as a tumoursuppressor gene. Trends Biochem Sci 24:73-76
34. Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, Lapertosa G, Iaquinto G, Sablich R, Gusmaroli R, Aste H, Giacosa A (2002) Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 97:225-229
35. Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D (2008) A systematic review and metaanalysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 103: 292-300
36. Cotsarelis G, Sun TT, Lavker RM (1990) Labelretaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61:1329-1337
37. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF (2000) Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 192:14-18
38. Csendes A, Maluenda F, Braghetto I, Csendes P, Henriquez A, Quesada MS (1993) Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis. Gut 34:21-27
39. De Lange T (2005) Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 70:197-204
40. DeMeester TR (2001) Clinical biology of the Barrett's metaplasia, dysplasia to carcinoma sequence. Surg Oncol 10:91-102
41. DeMeester SR, DeMeester TR (2000) Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 231:303-321
42. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053
43. Dixon MF, Neville PM, Mapstone NP, Moayyedi P, Axon AT (2001) Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro- oesophageal reflux? Gut 49: 359-363
44. Drovdlic CM, Goddard KA, Chak A, Brock W, Chessler L, King JF, Richter J, Falk GW, Johnston DK, Fisher JL, Grady WM, Lemeshow S, Eng C (2003) Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet 40:651-656
45. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61:3410-3418
46. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, Mutoh H, Sugano K (2003) Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 38:14-22
47. Fass R, Sampliner RE (2000) Extension of squamous epithelium into the proximal stomach: a newly recognized mucosal abnormality. Endoscopy 32:27-32
48. Fass R, Hell RW, Garewal HS, Martinez P, Pulliam G, Wendel C, Sampliner RE (2001) Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 48:310-313
49. Fitzgerald RC (2006) Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55:1810-1820
50. Fountoulakis A, Martin IG, White KL, Dixon MF, Cade JE, Sue-Ling HM, Wild CP (2004) Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus. Dig Dis Sci 49: 914-919
51. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ (1996) 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 93:7081-7084
52. Garrigue-Antar L, Souza RF, Vellucci VF, Meltzer SJ, Reiss M (1996) Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab Invest 75:263-272
53. Geboes K, Desmet V (1978) Histology of the esophagus. Front Gastrointest Res 3:1-17
54. Giaccia AJ, Kastan MB (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973-2983
55. Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TP (1988) Experimental columnar metaplasia in the canine oesophagus. Br J Surg 75:113-115
56. GOSPE (1991) Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Int J Cancer 48:364-368
57. Greaves LC, Preston SL, Tadrous PJ, Taylor RW, Barron MJ, Oukrif D, Leedham SJ, Deheragoda M, Sasieni P, Novelli MR, Jankowski JA, Turnbull DM, Wright NA, McDonald SA (2006) Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci USA 103:714-719
58. Gronemeyer H, Miturski R (2001) Molecular mechanisms of retinoid action. Cell Mol Biol Lett 6:3-52
59. Guillem PG (2005) How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci 50:415-424
60. Haggitt RC (1994) Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982-993
61. Haggitt RC (2000) Pathology of Barrett's esophagus. J Gastrointest Surg 4:117-118
62. Haggitt RC, Reid BJ, Rabinovitch PS, Rubin CE (1988) Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol 131:53-61
63. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G (1994) TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107:1012-1018
64. Hampel H, Abraham NS, El-Serag HB (2005) Metaanalysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199-211
65. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
66. Hanby AM, Wright NA (1993) The ulcer-associated cell lineage: the gastrointestinal repair kit? J Pathol 171:3-4
67. Hanby AM, Jankowski JA, Elia G, Poulsom R, Wright NA (1994) Expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in Barrett's metaplasia and the native oesophageal epithelium: delineation of epithelial phenotype. J Pathol 173:213-219
68. Harmon JW, Johnson LF, Maydonovitch CL (1981) Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 26:65-72
69. Hay ED, Zuk A (1995) Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 26:678-690
70. Hayward J (1961) The treatment of fibrous stricture of the oesophagus associated with hiatal hernia. Thorax 16:45-55
71. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, Luketich JD, Godfrey TE, Hughes SJ (2005) The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 7:75-84
72. Hiyama T, Yoshihara M, Tanaka S, Chayama K (2007) Genetic polymorphisms and esophageal cancer risk. Int J Cancer 121:1643-1658
73. Hopwood D, Milne G, Logan KR (1979) Electron microscopic changes in human oesophageal epithelium in oesophagitis. J Pathol 129:161-167
74. Iascone C, DeMeester TR, Little AG, Skinner DB (1983) Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 118:543-549
75. Iijima K, Grant J, McElroy K, Fyfe V, Preston T, McColl KE (2003) Novel mechanism of nitrosative stress from dietary nitrate with relevance to gastrooesophageal junction cancers. Carcinogenesis 24:1951-1960
76. Ireland AP, Shibata DK, Chandrasoma P, Lord RV, Peters JH, DeMeester TR (2000) Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 231:179-187
77. Jankowski J, Hoopwood D, Dover R, Wormsley KG (1992) Development and growth of normal, metaplastic and dysplastic oesophageal mucosa: biological markers of neoplasia. Eur J Gastroeneterol Hepatol 5:12
78. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS (1999) Molecular evolution of the metaplasiadysplasia- adenocarcinoma sequence in the esophagus. Am J Pathol 154:965-973
79. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C (2000) Barrett's metaplasia. Lancet 356:2079-2085
80. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T (2005) Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 53:35-69
81. Jimenez P, Piazuelo E, Sanchez MT, Ortego J, Soteras F, Lanas A (2005) Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. World J Gastroenterol 11:2697-2703
82. Johansson J, Hakansson HO, Mellblom L, Kempas A, Johansson KE, Granath F, Nyren O (2007) Risk factors for Barrett's oesophagus: a populationbased approach. Scand J Gastroenterol 42: 148-156
83. Johns BA (1952) Developmental changes in the oesophageal epithelium in man. J Anat 86: 431-442
84. Jones BE, Lo CR, Liu H, Pradhan Z, Garcia L, Srinivasan A, Valentino KL, Czaja MJ (2000) Role of caspases and NF-kappaB signaling in hydrogen peroxide- and superoxide-induced hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 278:G693-G699
85. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA (1995) Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 222:525-531; discussion 531-1523
86. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ (2000) Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92:1805-1811
87. Kerkhof M, Kusters JG, van Dekken H, Kuipers EJ, Siersema PD (2007) Biomarkers for risk stratification of neoplastic progression in Barrett esophagus. Cell Oncol 29:507-517
88. Khalbuss WE, Marousis CG, Subramanyam M, Orlando RC (1995) Effect of HCl on transmembrane potentials and intracellular pH in rabbit esophageal epithelium. Gastroenterology 108:662-672
89. Kivilaakso E, Fromm D, Silen W (1980) Effect of bile salts and related compounds on isolated esophageal mucosa. Surgery 87:280-285
90. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R (1998) Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115:1381-1386
91. Koike N, Higuchi T, Sakai Y (1990) Goblet-like cells in atrophic vaginal smears and their histologic correlation. Possible confusion with endocervical cells. Acta Cytol 34:785-788
92. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers ED, Dinjens WN, Bosman FT (1997) Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 182:331-338
93. Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, Buffler P, Corley DA (2008) Dietary patterns and the risk of Barrett's esophagus. Am J Epidemiol 167:839-846
94. Kyrgidis A, Kountouras J, Zavos C, Chatzopoulos D (2005) New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J Surg Res 125:189-212
95. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ (2007) Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 14:977-991
96. Li H, Walsh TN, O'Dowd G, Gillen P, Byrne PJ, Hennessy TP (1994) Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 115: 176-181
97. Lin L, Prescott MS, Zhu Z, Singh P, Chun SY, Kuick RD, Hanash SM, Orringer MB, Glover TW, Beer DG (2000) Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res 60:7021-7027
98. Liu RH, Hotchkiss JH (1995) Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat Res 339:73-89
99. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV (2000) Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4:135-142
100. Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV, DeMeester TR (2005) Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 138:924-931
101. Maley CC, Reid BJ (2005) Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol 15:474-483
102. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 64:3414-3427
103. Malfertheiner P, Peitz U (2005) The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut 54(Suppl 1):i13-i20
104. Marshall RE, Anggiansah A, Owen WA, Owen WJ (1997) The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease. Gut 40:182-187
105. Mates JM, Perez-Gomez C, Nunez de Castro I (1999) Antioxidant enzymes and human diseases. Clin Biochem 32:595-603
106. McColl KE (2005) When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 54:1-3
107. Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW (1994) Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 35: 1348-1351
108. Milano F, van Baal JW, Buttar NS, Rygiel AM, de Kort F, DeMars CJ, Rosmolen WD, Bergman JJ, VAM J, Wang KK, Peppelenbosch MP, Krishnadath KK (2007) Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132:2412-2421
109. Mittal RK, Balaban DH (1997) The esophagogastric junction. N Engl J Med 336:924-932
110. Mittal RK, Lange RC, McCallum RW (1987) Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 92:130-135
111. Moayyedi P (2008) Barrett's esophagus and obesity: the missing part of the puzzle. Am J Gastroenterol 103:301-303
112. Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR (2003) The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 29:890-894
113. Mobius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR (2005) COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 31:755-759
114. Moersch RN, Ellis FH Jr, Mc DJ (1959) Pathologic changes occurring in severe reflux esophagitis. Surg Gynecol Obstet 108:476-484
115. Montgomery EA, Hartmann DP, Carr NJ, Holterman DA, Sobin LH, Azumi N (1996) Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies. Am J Clin Pathol 106:298-304
116. Montgomery RK, Mulberg AE, Grand RJ (1999) Development of the human gastrointestinal tract: twenty years of progress. Gastroenterology 116: 702-731
117. Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, Siersema PD, Kusters JG (2004) The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 57:1063-1068
118. Morales CP, Souza RF, Spechler SJ (2002) Hallmarks of cancer progression in Barrett's oesophagus. Lancet 360:1587-1589
119. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96:990-996
120. Murray AW (2004) Recycling the cell cycle: cyclins revisited. Cell 116:221-234
121. Nair KS, Naidoo R, Chetty R (2005) Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 58:343-351
122. Nehra D, Howell P, Williams CP, Pye JK, Beynon J (1999) Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 44:598-602
123. Neumann CS, Cooper BT (1994) 24 hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus. Gut 35:1352-1355
124. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV (2005) Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia- dysplasiaadenocarcinoma sequence in the esophagus. Am J Gastroenterol 100:1257-1264
125. Olliver JR, Hardie LJ, Gong Y, Dexter S, Chalmers D, Harris KM, Wild CP (2005) Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 14:620-625
126. Park YS, Park HJ, Kang GH, Kim CJ, Chi JG (2003) Histology of gastroesophageal junction in fetal and pediatric autopsy. Arch Pathol Lab Med 127:451-455
127. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK (1976) The histologic pectrum of Barrett's esophagus. N Engl J Med 295:476-480
128. Pera M, Brito MJ, Poulsom R, Riera E, Grande L, Hanby A, Wright NA (2000) Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis 21:1587-1591
129. Phillips RW, Frierson HF Jr, Moskaluk CA (2003) Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 27:1442-1447
130. Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN, Meltzer SJ (1994) APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 107:1759-1763
131. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187:112-126
132. Radominska-Pandya A, Chen G (2002) Photoaffinity labeling of human retinoid X receptor beta (RXRbeta) with 9-cis-retinoic acid: identification of phytanic acid, docosahexaenoic acid, and lithocholic acid as ligands for RXRbeta. Biochemistry 41:4883-4890
133. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P (2008) Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 67:394-398
134. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC (2006) In vivo and in vitro evidence for transforming growth factor-beta1- mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 66: 9583-9590
135. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC (1998) p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83:7-18
136. Richter JE (2000) Importance of bile reflux in Barrett's esophagus. Dig Dis 18:208-216
137. Robert V, Michel P, Flaman JM, Chiron A, Martin C, Charbonnier F, Paillot B, Frebourg T (2000) High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis 21:563-565
138. Rochat A, Kobayashi K, Barrandon Y (1994) Location of stem cells of human hair follicles by clonal analysis. Cell 76:1063-1073
139. Romero Y, Cameron AJ, Locke GR 3rd, Schaid DJ, Slezak JM, Branch CD, Melton LJ 3rd (1997) Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 113:1449-1456
140. Safaie-Shirazi S (1977) Effect of pepsin on ionic permeability of canine esophageal mucosa. J Surg Res 22:5-8
141. Salo JA, Lehto VP, Kivilaakso E (1983) Morphological alterations in experimental esophagitis. Light microscopic and scanning and transmission electron microscopic study. Dig Dis Sci 28:440-448
142. Sampliner RE (1998) Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 93:1028-1032
143. Sappati Biyyani RS, Chessler L, McCain E, Nelson K, Fahmy N, King J (2007) Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. Dis Esophagus 20:53-57
144. Sarbia M, Bektas N, Muller W, Heep H, Borchard F, Gabbert HE (1999) Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer 86:2597-2601
145. Sarosi G, Brown G, Jaiswal K, Feagins LA, Lee E, Crook TW, Souza RF, Zou YS, Shay JW, Spechler SJ (2008) Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 21:43-50
146. Sawhney RA, Shields HM, Allan CH, Boch JA, Trier JS, Antonioli DA (1996) Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig Dis Sci 41:1088-1098
147. Schmidt PH, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA, Goldenring JR (1999) Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 79:639-646
148. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR (2000) P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 6:3153-3158
149. Schorah CJ, Sobala GM, Sanderson M, Collis N, Primrose JN (1991) Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis. Am J Clin Nutr 53:287S-293S
150. Seery JP (2002) Stem cells of the oesophageal epithelium. J Cell Sci 115:1783-1789
151. Seery JP, Watt FM (2000) Asymmetric stem-cell divisions define the architecture of human oesophageal epithelium. Curr Biol 10:1447-1450
152. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119:333-338
153. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791
154. Shields HM, Zwas F, Antonioli DA, Doos WG, Kim S, Spechler SJ (1993) Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. Dig Dis Sci 38:97-108
155. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G (2000) Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118:487-496
156. Singh AB, Harris RC (2005) Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17:1183-1193
157. Singh P, Taylor RH, Colin-Jones DG (1994) Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 89:349-356
158. Sital RR, Kusters JG, De Rooij FW, Kuipers EJ, Siersema PD (2006) Bile acids and Barrett's oesophagus: a sine qua non or coincidence? Scand J Gastroenterol Suppl:11-17
159. Slack JM (2000) Stem cells in epithelial tissues. Science 287:1431-1433
160. Sloan S, Kahrilas PJ (1991) Impairment of esophageal emptying with hiatal hernia. Gastroenterology 100:596-605
161. Sloan S, Rademaker AW, Kahrilas PJ (1992) Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 117:977-982
162. Smedts F, Ramaekers FC, Vooijs PG (1993) The dynamics of keratin expression in malignant transformation of cervical epithelium: a review. Obstet Gynecol 82:465
163. Sodhani P, Gupta S, Prakash S, Singh V (1999) Columnar and metaplastic cells in vault smears: cytologic and colposcopic study. Cytopathology 10:122-126; discussion 131
164. Souza RF, Garrigue-Antar L, Lei J, Yin J, Appel R, Vellucci VF, Zou TT, Zhou X, Wang S, Rhyu MG, Cymes K, Chan O, Park WS, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Simms L, Leggett B, Young J, Harpaz N, Reiss M, Meltzer SJ (1996) Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum Cell 9:229-236
165. Souza RF, Morales CP, Spechler SJ (2001) Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 15:1087-1100
166. Spechler SJ, Goyal RK (1986) Barrett's esophagus. N Engl J Med 315:362-371
167. Stein HJ, Siewert JR (1993) Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management. Dysphagia 8:276-288
168. Stein HJ, DeMeester TR, Naspetti R, Jamieson J, Perry RE (1991) Three-dimensional imaging of the lower esophageal sphincter in gastroesophageal reflux disease. Ann Surg 214:374-383; discussion 383-1374
169. Stein HJ, Barlow AP, DeMeester TR, Hinder RA (1992) Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg 216:35-43
170. Suzuki H, Iijima K, Scobie G, Fyfe V, McColl KE (2005) Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut 54:1527-1535
171. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
172. Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740-746
173. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ (2007) Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 26: 1465-1477
174. Tosh D, Slack JM (2002) How cells change their phenotype. Nat Rev Mol Cell Biol 3:187-194
175. Tuynman JB, Buskens CJ, Kemper K, ten Kate FJ, Offerhaus GJ, Richel DJ, van Lanschot JJ (2005) Neoadjuvant selective COX-2 inhibition downregulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242:840-849, discussion 849-850
176. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ (2008) Met expression is an independent prognostic risk factor in patients with
177. Tytgat GN (1995) Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any real value? Endoscopy 27:19-26
178. Vaezi MF, Richter JE (1995) Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 117:699-704
179. Vaezi MF, Richter JE (1996) Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111:1192-1199
180. van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, Wang KK, Peppelenbosch MP, Krishnadath KK (2005) A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 129:1274-1281
181. van Baal JW, Bozikas A, Pronk R, Ten Kate FJ, Milano F, Rygiel AM, Rosmolen WD, Peppelenbosch MP, Bergman JJ, Krishnadath KK (2008) Cytokeratin and CDX-2 expression in Barrett's esophagus. Scand J Gastroenterol 43:132-140
182. Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99:860-868
183. Von Rahden BH, Stein HJ, Feith M, Puhringer F, Theisen J, Siewert JR, Sarbia M (2006) Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 45:786-794
184. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658-667
185. Wetscher GJ, Hinder RA, Bagchi D, Hinder PR, Bagchi M, Perdikis G, McGinn T (1995) Reflux esophagitis in humans is mediated by oxygenderived free radicals. Am J Surg 170:552-556; discussion 556-557
186. Wijnhoven BP, Dinjens WN, Pignatelli M (2000) E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87:992-1005
187. Wijnhoven BP, Tilanus HW, Dinjens WN (2001) Molecular biology of Barrett's adenocarcinoma. Ann Surg 233:322-337
188. Wild CP, Hardie LJ (2003) Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3:676-684
189. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, Geradts J, Javle M, Brattain M (2004) Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8:448-453
190. Williams LJ, Guernsey DL, Casson AG (2006) Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Curr Oncol 13:33-43
191. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58:2929-2934
192. Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MSet al. (1987) Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92:118-124
193. Wright NA (1996) Migration of the ductular elements of gut-associated glands gives clues to the histogenesis of structures associated with responses to acid hypersecretory state: the origins of "gastric metaplasia" in the duodenum of the specialized mucosa of Barrett's esophagus and of pseudopyloric metaplasia. Yale J Biol Med 69:147-153
194. Yacoub L, Goldman H, Odze RD (1997) Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol 10:105-112
195. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135-142
196. Yamamoto K, Arakawa T, Ueda N, Yamamoto S (1995) Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270:31315-31320
197. Younes M, Lebovitz RM, Lechago LV, Lechago J (1993) p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a followup study. Gastroenterology 105:1637-1642
198. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L (2008) The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 168:237-249
199. Yu WY, Slack JM, Tosh D (2005) Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev Biol 284:157-170
200. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS (2005) Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet 366:1640-1649